Directorate Change

Kromek

08/05/2025 07:05

RNS Number : 7855H

Kromek Group PLC

08 May 2025

 

8 May 2025

 

Kromek Group plc 

("Kromek" or the "Company" or the "Group") 

 

Directorate Change

 

Kromek Group plc (AIM: KMK), a leading developer of radiation and bio-detection technology solutions for the advanced imaging and CBRN detection segments, announces that Claire Burgess will be appointed as a Director, Chief Financial Officer ("CFO") and Company Secretary of the Group and that Paul Farquhar is retiring and will therefore resign as a Director, CFO and Company Secretary of the Group, both with effect from 1 June 2025. Ms. Burgess will join Kromek on 12 May 2025 to allow for a period of handover ahead of her assuming her new role.

 

Claire Burgess has spent over 12 years in senior financial positions in businesses in the UK and US, primarily in the engineering and technology sectors. Most recently, Ms. Burgess was Financial Director of Advanced Electric Machines Group Ltd ("AEM"), a designer and manufacturer of magnet-free electric powertrain technologies. Other experience includes being CFO of group companies JB Processing and TBGS Holdings and being responsible for establishing and building the US subsidiaries, including the acquisition of the Alabama White Marble Quarry. She is a qualified Fellow Chartered Accountant, having begun her career as an auditor at Ernst & Young before joining KPMG as a Corporate Finance Executive. 

Rakesh Sharma OBE FREng, Chairman of Kromek, said: "On behalf of the Board, I would like to thank Paul for his contribution to Kromek. The business is in a fundamentally stronger position than when he joined, and we wish him all the best for his retirement. I would also like to welcome Claire to Kromek and to the Board. Her experience with growing technology and engineering-based companies with international operations is well-suited to the Kromek of today. We look forward to benefiting from her expertise as we continue to execute on our strategy."

 

Other than as set out below, there are no other matters required to be disclosed pursuant to paragraph (g) of Schedule Two to the AIM Rules for Companies as regards Ms. Burgess' appointment. Ms. Burgess does not have an interest in the ordinary shares of the Group.

 

Claire Louise Burgess (née Dyson)

 

The following information regarding the appointment of Claire Burgess, aged 51, is disclosed under Schedule 2(g) of the AIM Rules for Companies:

 

 

Current directorships and/or partnerships
Former directorships and/or partnerships (within the last 5 years)
Advanced Electric Machines Group Limited
Advanced Electric Machines Limited
Advanced Electric Machines Research Limited
Inn Collection (Bassenthwaite) Limited
Inn Collection Lakes (Ambleside) Limited
Inn Collection (Whitby) Limited
Inn Collection (Northallerton) Limited
Inn Collection (Helmsley) Limited
Inn Collection (Seaburn) Limited
Inn Collection Lakes (Coniston) Limited
Vindolanda Bidco Limited
Lindisfarne Inns Limited
Inn Collection Limited
Inn Collection AcquisitionCo Limited
Inn Collection Topco Limited
Inn Collection Midco Limited
Durham Vale Developments Limited
Vindolanda Midco 1 Limited
Marshall Inns Limited
Greensfield Moor Development Limited
Lindisfarne Inns (Bamburgh Castle) Limited
Inn Collection Bidco Limited
Vindolanda Topco Limited
Vindolanda Midco 2 Limited
Inn Collection Management Limited
Inn Collection Lakes (Ambleside) Limited

 

Ms. Burgess does not hold any shares in Kromek.

There are no further disclosures to be made under Rule 17 and Schedule 2(g) of the AIM Rules for Companies.

 

 

 

For further information, please contact: 

  

Kromek Group plc
Arnab Basu, CEO
Paul Farquhar, CFO
+44 (0)1740 626 060
Cavendish Capital Markets Limited (Nominated Adviser and Broker)
Geoff Nash/Giles Balleny/Seamus Fricker - Corporate Finance
Tim Redfern - ECM
Michael Johnson - Sales
+44 (0)20 7220 0500
Gracechurch Group (Financial PR)
Harry Chathli/Claire Norbury/Henry Gamble
+44 (0)20 4582 3500

 

Kromek Group plc 

 

Kromek Group plc is a leading developer of radiation detection and bio-detection technology solutions for the advanced imaging and CBRN detection segments. Headquartered in County Durham, UK, Kromek has manufacturing operations in the UK and US, delivering on the vision of enhancing the quality of life through innovative detection technology solutions.  

 

The advanced imaging segment comprises the medical (including CT and SPECT), security and industrial markets. Kromek provides its OEM customers with detector components, based on its core cadmium zinc telluride (CZT) platform, to enable better detection of diseases such as cancer and Alzheimer's, contamination in industrial manufacture and explosives in aviation settings.  

 

In CBRN detection, the Group provides nuclear radiation detection solutions to the global homeland defence and security market. Kromek's compact, handheld, high-performance radiation detectors, based on advanced scintillation and solid-state readout technology, are primarily used to protect critical infrastructure, events, personnel and urban environments from the threat of 'dirty bombs'.  

 

The Group is also developing bio-security solutions in the CBRN detection segment. These consist of fully automated and autonomous systems to detect a wide range of airborne pathogens.  

 

Kromek is listed on AIM, a market of the London Stock Exchange, under the trading symbol 'KMK'.  

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 
  END

 

 
BOAFFFFLEAIDIIE